Katharina Gasser – Managing Director, Biogen Switzerland
Biogen Switzerland’s Dr med Katharina Gasser outlines how her affiliate navigated the COVID-19 pandemic from an organisational and communication…
Tagged with Rare Diseases
Canada: Federal Consultations on a National Strategy for Rare…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada's consultation with Canadians on…
Public Insurance Coverage for Rare Disease Patients in China:…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the findings of the first ever analysis into…
Marc-Olivier Geinoz – CEO, Dipharma SA
Dipharma SA is a Swiss specialty pharmaceutical company, developing improved generics medicines for rare metabolic diseases. Founder & CEO…
NORD Chief Strategy Officer on Health Equity’s Vital…
With Rare Disease Day coming up on February 28th, one of the leading organizations dedicated to serving affected patients in the US, the National…
5 US Rare Disease Start-Ups to Watch
Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan therapies in Europe, here we move to…
5 European Rare Disease Start-Ups to Watch
With Rare Disease Day falling on 28 February, PharmaBoardroom dedicates this month to exploring the global rare disease landscape, highlighting key…
Biogen’s Swiss Head on Benefits of Diverse Experience…
A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before…
Top 10 Global Rare Disease Companies
The Top 10 rare disease companies globally, ranked by worldwide orphan drug sales for 2018. Celgene takes top spot, followed by Roche and Novartis.…
Ipsen CEO David Loew on M&A, Rare Disease Expansion, Niche…
In a wide-ranging and exclusive interview with PharmaBoardroom, Ipsen CEO David Loew looks back on an atypical first 100 days at the helm of the…
Rare Disease Strategies in the Booming US Market
Rare disease – defined in the US as a disease with a maximum patient population of 200,000 – is perhaps the most salient issue at the nexus of…
Pierre Morneau – General Manager, Takeda Switzerland
Pierrre Morneau of Takeda Switzerland explains the therapeutic areas at the core of the company, equitable access, the Swiss framework for rare…
